https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/STVN/stevanato-group-q3-2026-results-release BiopharmaWatch en 2026-10-20T20:30:00.000Z Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2027-q2 BiopharmaWatch en 2026-10-20T20:30:00.000Z STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026 https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-pda-conference-2026 BiopharmaWatch en 2026-10-20T20:25:00.000Z Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026 https://www.biopharmawatch.com/news/AMGN/amgen-presents-esmo-2026 BiopharmaWatch en 2026-10-20T20:15:00.000Z AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-q3-2026-conference-call BiopharmaWatch en 2026-10-20T20:15:00.000Z Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5 https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-10-20T20:13:51.085Z FDA Calendar Q4 2026: Key PDUFA Dates and Upcoming Approvals https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-10-20T20:13:00.000Z AN2 Therapeutics to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/RCEL/avita-medical-q3-2026-financial-results BiopharmaWatch en 2026-10-20T20:10:00.000Z AVITA Medical to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KRMD/koru-medical-q3-2026-financial-results-report BiopharmaWatch en 2026-10-20T20:05:00.000Z KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/VRTX/vertex-appoints-daniel-brennan-board-directors BiopharmaWatch en 2026-10-20T20:05:00.000Z Vertex Appoints Daniel Brennan to its Board of Directors https://www.biopharmawatch.com/news/INO/inovio-favorable-judgment-vgxi-geneone BiopharmaWatch en 2026-10-20T20:05:00.000Z INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science https://www.biopharmawatch.com/news/ILMN/illumina-webcast-upcoming-investor-conference-20261020 BiopharmaWatch en 2026-10-20T20:05:00.000Z Illumina To Webcast Upcoming Investor Conference https://www.biopharmawatch.com/news/LFMD/lifemd-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T20:05:00.000Z LifeMD to Report Third Quarter 2026 Financial Results on November 9 https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-20261020 BiopharmaWatch en 2026-10-20T20:05:00.000Z Intuitive Announces Third Quarter Earnings https://www.biopharmawatch.com/news/RXST/rxsight-q3-2026-financial-results-report BiopharmaWatch en 2026-10-20T20:05:00.000Z RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3 https://www.biopharmawatch.com/news/CBLL/ceribell-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T20:05:00.000Z Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/TKNO/teknova-announces-public-offering-common-stock BiopharmaWatch en 2026-10-20T20:02:00.000Z Teknova Announces Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/BRKR/bruker-q3-2026-earnings-release-webcast BiopharmaWatch en 2026-10-20T20:01:00.000Z Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-scott-wasserman BiopharmaWatch en 2026-10-20T20:01:00.000Z Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors https://www.biopharmawatch.com/news/TKNO/teknova-preliminary-q3-2026-financial-results BiopharmaWatch en 2026-10-20T20:01:00.000Z Teknova Announces Preliminary Third Quarter Financial Results https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q3-2026-results-report BiopharmaWatch en 2026-10-20T20:00:00.000Z Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/CORT/2026-ada-easd-consensus-report-hypercortisolism-screening BiopharmaWatch en 2026-10-20T20:00:00.000Z 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes https://www.biopharmawatch.com/news/ALKS/alkermes-third-quarter-financial-results-november-2026 BiopharmaWatch en 2026-10-20T20:00:00.000Z Alkermes to Report Third Quarter Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/AVXL/anavex-corporate-update-blarcamesine-studies BiopharmaWatch en 2026-10-20T20:00:00.000Z Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies https://www.biopharmawatch.com/news/GEHC/ge-healthcare-global-collaborations-theranostics-imaging BiopharmaWatch en 2026-10-20T16:39:00.000Z GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging https://www.biopharmawatch.com/news/RKTO/rocket-one-ai-chip-development-agreement BiopharmaWatch en 2026-10-20T14:40:53.000Z Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing https://www.biopharmawatch.com/news/ONCY/oncolytics-reo-033-trial-esmo-2026 BiopharmaWatch en 2026-10-20T13:35:00.000Z Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer https://www.biopharmawatch.com/news/NTHI/neonc-technologies-catalyst-season-fda-meeting BiopharmaWatch en 2026-10-20T13:33:00.000Z Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season https://www.biopharmawatch.com/news/ELOX/eloxx-phase-2-express-study-design-adpkd BiopharmaWatch en 2026-10-20T13:31:00.000Z Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer https://www.biopharmawatch.com/news/HCTI/hcti-expands-ai-business-new-contracts-revenue BiopharmaWatch en 2026-10-20T13:20:00.000Z HCTI Expands AI Business with 6 New Contracts, Targeting approx. $4.65M in Annual Run Rate Revenue https://www.biopharmawatch.com/news/CODX/comira-diagnostics-nuwatin-2026-forum-participation BiopharmaWatch en 2026-10-20T13:15:00.000Z Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum https://www.biopharmawatch.com/news/CELZ/creative-medical-ultrasome-knee-osteoarthritis-study BiopharmaWatch en 2026-10-20T13:15:00.000Z Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study https://www.biopharmawatch.com/news/SNY/scionxbio-sanofi-collaboration-xrna-therapeutics BiopharmaWatch en 2026-10-20T13:10:00.000Z ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics https://www.biopharmawatch.com/news/GH/guardant-health-liquid-biopsy-esmo-congress-2026 BiopharmaWatch en 2026-10-20T13:02:00.000Z Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 https://www.biopharmawatch.com/news/CVS/minuteclinic-opens-new-clinics-massachusetts BiopharmaWatch en 2026-10-20T13:00:00.000Z MinuteClinic® opens three new retail medical clinics to serve Massachusetts patients https://www.biopharmawatch.com/news/PEN/penumbra-cavt-technology-fda-clearance-dvt BiopharmaWatch en 2026-10-20T13:00:00.000Z Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) https://www.biopharmawatch.com/news/AMGN/tezspire-eosinophilic-esophagitis-trial-results BiopharmaWatch en 2026-10-20T13:00:00.000Z TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS https://www.biopharmawatch.com/news/OMDA/omada-health-glp-1-care-track-research-presentation BiopharmaWatch en 2026-10-20T13:00:00.000Z Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress https://www.biopharmawatch.com/news/FEMY/femasys-sandsrx-partnership-femaseed-launch BiopharmaWatch en 2026-10-20T13:00:00.000Z Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs https://www.biopharmawatch.com/news/SCNI/scinai-ceo-shareholder-update-cdmo-growth BiopharmaWatch en 2026-10-20T12:49:00.000Z Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-launches-tru-niagen-skincare BiopharmaWatch en 2026-10-20T12:32:00.000Z Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product https://www.biopharmawatch.com/news/ACRV/acrivon-advances-acr-7280-cdk11-inhibitor-ind-filing-2027 BiopharmaWatch en 2026-10-20T12:30:55.000Z Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 https://www.biopharmawatch.com/news/VTGN/vistagen-gatc-health-predictive-ai-collaboration BiopharmaWatch en 2026-10-20T12:30:54.000Z Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-study-nbi-567-alzheimers BiopharmaWatch en 2026-10-20T12:30:00.000Z Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-kidney-cancer-opportunity BiopharmaWatch en 2026-10-20T12:30:00.000Z Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer https://www.biopharmawatch.com/news/WGS/genedx-expands-diagnostic-leadership-long-read-sequencing BiopharmaWatch en 2026-10-20T12:30:00.000Z GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis https://www.biopharmawatch.com/news/MYGN/myriad-genetics-labcorp-prenatal-health-sale BiopharmaWatch en 2026-10-20T12:30:00.000Z Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp https://www.biopharmawatch.com/news/OPTH/optimi-health-mdma-production-phase-3-ptsd-trial BiopharmaWatch en 2026-10-20T12:30:00.000Z Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-craig-blanchette-svp-research BiopharmaWatch en 2026-10-20T12:30:00.000Z Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) https://www.biopharmawatch.com/news/FRNM/freenome-launches-simplescreen-lung-cancer-test BiopharmaWatch en 2026-10-20T12:30:00.000Z Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option https://www.biopharmawatch.com/news/MBOT/microbot-medical-new-patents-global-ip-portfolio BiopharmaWatch en 2026-10-20T12:30:00.000Z Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2026-financial-results BiopharmaWatch en 2026-10-20T12:30:00.000Z Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026 https://www.biopharmawatch.com/news/MBRX/moleculin-ceo-corner-annamycin-miracle-trial-progress BiopharmaWatch en 2026-10-20T12:12:30.000Z Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-results-ueg-week-2026 BiopharmaWatch en 2026-10-20T12:05:00.000Z Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q3-2026-results-report BiopharmaWatch en 2026-10-20T12:05:00.000Z Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/WAT/waters-quest-diagnostics-hpv-screening-access BiopharmaWatch en 2026-10-20T12:00:00.000Z Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-unveils-atnm-400-data-eanm-2026-first-human BiopharmaWatch en 2026-10-20T12:00:00.000Z Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer https://www.biopharmawatch.com/news/SRRK/scholar-rock-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T12:00:00.000Z Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/RVTY/revvity-launches-signals-labgistics-solution BiopharmaWatch en 2026-10-20T12:00:00.000Z Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows https://www.biopharmawatch.com/news/SNY/duvakitug-phase-2b-results-ueg-week-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q3-2026-results-webcast BiopharmaWatch en 2026-10-20T12:00:00.000Z Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-parkinsons-disease-ana-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting https://www.biopharmawatch.com/news/SLDB/solid-biosciences-research-esgct-2026 BiopharmaWatch en 2026-10-20T12:00:00.000Z Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026 https://www.biopharmawatch.com/news/INNV/innovage-fiscal-q1-2027-results-conference-call BiopharmaWatch en 2026-10-20T12:00:00.000Z InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026 https://www.biopharmawatch.com/news/VERA/vera-therapeutics-asn-kidney-week-webcast BiopharmaWatch en 2026-10-20T12:00:00.000Z Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-3-trial-zoldonrasib BiopharmaWatch en 2026-10-20T12:00:00.000Z Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-new-board-members BiopharmaWatch en 2026-10-20T12:00:00.000Z PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-joiiup-ai-cancer-risk-assessment BiopharmaWatch en 2026-10-20T12:00:00.000Z YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs https://www.biopharmawatch.com/news/ICCM/icecure-enrolls-first-patients-choicestudy BiopharmaWatch en 2026-10-20T11:55:00.000Z IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites https://www.biopharmawatch.com/news/JNJ/johnson-johnson-shockwave-c2-aero-fly-launch BiopharmaWatch en 2026-10-20T11:45:00.000Z Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half https://www.biopharmawatch.com/news/STXS/stereotaxis-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T11:40:00.000Z Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-results-atnm-400 BiopharmaWatch en 2026-10-20T11:30:00.000Z Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models https://www.biopharmawatch.com/news/NGNE/neurogene-ngn-401-rett-syndrome-esgct-congress BiopharmaWatch en 2026-10-20T11:30:00.000Z Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-q3-2026-financial-results-call BiopharmaWatch en 2026-10-20T11:30:00.000Z Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call https://www.biopharmawatch.com/news/ARDX/ardelyx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-20T11:30:00.000Z Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/NBP/visara-acquires-yol104-2-ossn BiopharmaWatch en 2026-10-20T11:00:00.000Z Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia https://www.biopharmawatch.com/news/UTHR/united-therapeutics-expands-xenograft-production-facility BiopharmaWatch en 2026-10-20T11:00:00.000Z United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-od-001-results BiopharmaWatch en 2026-10-20T11:00:00.000Z Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 https://www.biopharmawatch.com/news/ACON/aclarion-ceo-shareholder-letter-q3-2026 BiopharmaWatch en 2026-10-20T11:00:00.000Z Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-2026-q3-conference-call BiopharmaWatch en 2026-10-20T10:45:00.000Z Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026 https://www.biopharmawatch.com/news/BNTX/biontech-q3-2026-financial-results-update BiopharmaWatch en 2026-10-20T10:45:00.000Z BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-q3-2026-conference-call-webcast BiopharmaWatch en 2026-10-20T10:30:00.000Z Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-publishes-paper-qrx003-netherton-syndrome BiopharmaWatch en 2026-10-20T10:30:00.000Z Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy https://www.biopharmawatch.com/news/PSNL/personalis-resistance-mutation-tracking-next-personal-mrd-test BiopharmaWatch en 2026-10-20T10:00:00.000Z Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-phase-2-trial-results-rap-219 BiopharmaWatch en 2026-10-20T10:00:00.000Z Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania https://www.biopharmawatch.com/news/ALVO/alvotech-fda-approval-simlandi-manufacturing-process BiopharmaWatch en 2026-10-20T08:30:00.000Z Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch https://www.biopharmawatch.com/news/OCS/oculis-phase-2-acuity-trial-privosegtor-presentation BiopharmaWatch en 2026-10-20T06:00:00.000Z Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-q3-2026-update BiopharmaWatch en 2026-10-20T05:00:00.000Z Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquisition-sod-sciences BiopharmaWatch en 2026-10-19T21:01:00.000Z Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel https://www.biopharmawatch.com/news/ATEC/atec-third-quarter-2026-financial-results-webcast BiopharmaWatch en 2026-10-19T20:35:00.000Z ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/HAE/haemonetics-fda-approval-perqseal-elite-system BiopharmaWatch en 2026-10-19T20:15:00.000Z Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-third-quarter-results-november-2026 BiopharmaWatch en 2026-10-19T20:15:00.000Z Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-obesityweek-2026-presentations BiopharmaWatch en 2026-10-19T20:13:00.000Z Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026 https://www.biopharmawatch.com/news/SIBN/si-bone-q3-2026-financial-results-report BiopharmaWatch en 2026-10-19T20:09:00.000Z SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/WGS/genedx-advances-genomic-medicine-ashg-2026 BiopharmaWatch en 2026-10-19T20:05:00.000Z GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026 https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-dmd-update BiopharmaWatch en 2026-10-19T20:05:00.000Z CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM https://www.biopharmawatch.com/news/IART/integra-completes-refinancing-transactions BiopharmaWatch en 2026-10-19T20:05:00.000Z Integra Announces Completion of Refinancing Transactions https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-cfo-transition BiopharmaWatch en 2026-10-19T20:05:00.000Z CRISPR Therapeutics Announces Chief Financial Officer Transition https://www.biopharmawatch.com/news/FTRE/fortrea-acquisition-early-phase-services BiopharmaWatch en 2026-10-19T20:05:00.000Z Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-board-appointments BiopharmaWatch en 2026-10-19T20:05:00.000Z Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-esmo-congress-2026-presentation BiopharmaWatch en 2026-10-19T20:05:00.000Z Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 https://www.biopharmawatch.com/news/SOLV/solventum-fda-clearance-restrata-vac-therapy BiopharmaWatch en 2026-10-19T20:05:00.000Z Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy* https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-appoints-geno-germano-board BiopharmaWatch en 2026-10-19T20:05:00.000Z Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors https://www.biopharmawatch.com/news/CERS/cerus-corporation-q3-2026-financial-results-release BiopharmaWatch en 2026-10-19T20:01:00.000Z Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/DCTH/delcath-systems-esmo-congress-2026 BiopharmaWatch en 2026-10-19T20:01:00.000Z Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma https://www.biopharmawatch.com/news/IRON/disc-medicine-350-million-offering BiopharmaWatch en 2026-10-19T20:01:00.000Z Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/HTFL/heartflow-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-19T20:01:00.000Z Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261019 BiopharmaWatch en 2026-10-19T20:01:00.000Z Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CTY/city-therapeutics-ipo-230-million BiopharmaWatch en 2026-10-19T20:01:00.000Z City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-19T20:00:00.000Z Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-third-quarter-results-october-2026 BiopharmaWatch en 2026-10-19T20:00:00.000Z Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 https://www.biopharmawatch.com/news/ANAB/jemperli-approval-msi-h-dmmr-rectal-cancer BiopharmaWatch en 2026-10-19T18:18:00.000Z Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer https://www.biopharmawatch.com/news/ASTH/alignment-health-plan-asth-partner-expand-access-care BiopharmaWatch en 2026-10-19T15:00:00.000Z Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors https://www.biopharmawatch.com/news/SNY/sanofi-2026-ispe-facility-of-the-year-award BiopharmaWatch en 2026-10-19T14:03:00.000Z ISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus Project https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-october-2026 BiopharmaWatch en 2026-10-19T13:54:27.000Z Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/BCDA/biocardia-fda-acceptance-helix-catheter BiopharmaWatch en 2026-10-19T13:15:00.000Z BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-kidney-week-2026-advancements BiopharmaWatch en 2026-10-19T13:00:00.000Z Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/RXST/rxsight-appoints-eye-care-leaders-commercial-transformation BiopharmaWatch en 2026-10-19T13:00:00.000Z RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation https://www.biopharmawatch.com/news/XBIT/xbiotech-positive-phase-ii-results-taskin-trial BiopharmaWatch en 2026-10-19T13:00:00.000Z XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/DARE/dare-bioscience-hermedicine-educational-program BiopharmaWatch en 2026-10-19T12:56:00.000Z Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-signs-global-pharmaceutical-intelligence-partner BiopharmaWatch en 2026-10-19T12:45:00.000Z OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market https://www.biopharmawatch.com/news/SPRC/scisparc-shifts-focus-agentic-ai-cybersecurity-finance BiopharmaWatch en 2026-10-19T12:35:00.000Z SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications https://www.biopharmawatch.com/news/OSTX/os-therapies-warrant-exercise-inducement BiopharmaWatch en 2026-10-19T12:30:00.000Z OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million https://www.biopharmawatch.com/news/FBLG/fibrobiologics-preclinical-data-fsdc-spheroids-nass-2026 BiopharmaWatch en 2026-10-19T12:30:00.000Z FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting https://www.biopharmawatch.com/news/DWTX/dogwood-secures-5-million-investment-ck-life-sciences BiopharmaWatch en 2026-10-19T12:30:00.000Z Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. https://www.biopharmawatch.com/news/WVE/wave-life-sciences-virtual-research-day-november-2026 BiopharmaWatch en 2026-10-19T12:30:00.000Z Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/INDV/indivior-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-19T12:30:00.000Z Indivior to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SUPN/supernus-announces-q3-2026-results-conference-call BiopharmaWatch en 2026-10-19T12:30:00.000Z Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-ketamine-manufacturing-validation BiopharmaWatch en 2026-10-19T12:30:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine https://www.biopharmawatch.com/news/NRSN/neurosense-patent-application-traumatic-brain-injury BiopharmaWatch en 2026-10-19T12:25:00.000Z NeuroSense Files U.S. Patent Application for Traumatic Brain Injury https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-data BiopharmaWatch en 2026-10-19T12:23:00.000Z Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula https://www.biopharmawatch.com/news/ENLV/enlivex-cost-reduction-phase-2b-trial-allocetra-knee-oa BiopharmaWatch en 2026-10-19T12:17:00.000Z Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis https://www.biopharmawatch.com/news/RIGL/rigel-gavreto-data-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:05:00.000Z Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 https://www.biopharmawatch.com/news/SER/enable-injections-approval-japan-circliq-injector BiopharmaWatch en 2026-10-19T12:04:00.000Z Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-ttx-mc138-esmo-2026 BiopharmaWatch en 2026-10-19T12:04:00.000Z TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 https://www.biopharmawatch.com/news/AVBP/firmonertinib-egfr-pacc-mutant-nsclc-results BiopharmaWatch en 2026-10-19T12:01:00.000Z ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-fistula-remission BiopharmaWatch en 2026-10-19T12:00:00.000Z Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula https://www.biopharmawatch.com/news/INVA/innoviva-specialty-therapeutics-idweek-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026 https://www.biopharmawatch.com/news/ESTA/establishment-labs-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-19T12:00:00.000Z Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29 https://www.biopharmawatch.com/news/GILD/gilead-present-new-data-hiv-antiviral-idweek-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 https://www.biopharmawatch.com/news/SLN/merck-acquires-silence-therapeutics-sirna-asset BiopharmaWatch en 2026-10-19T12:00:00.000Z Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset https://www.biopharmawatch.com/news/SLN/silence-therapeutics-acquired-merck-kgaa BiopharmaWatch en 2026-10-19T12:00:00.000Z Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany https://www.biopharmawatch.com/news/RDHL/nci-grant-redhill-opaganib-car-t-cell-multiple-myeloma BiopharmaWatch en 2026-10-19T12:00:00.000Z $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-trading-update BiopharmaWatch en 2026-10-19T12:00:00.000Z Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today https://www.biopharmawatch.com/news/IMMP/immutep-imp761-poster-acr-convergence-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-long-covid-ana-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-aasld-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/RMD/resmed-launch-airtouch-f40-cpap-mask-us BiopharmaWatch en 2026-10-19T12:00:00.000Z Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S. https://www.biopharmawatch.com/news/HYPD/hyperion-defi-third-quarter-earnings-call-november-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardiology-conferences BiopharmaWatch en 2026-10-19T12:00:00.000Z Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2026-financial-results-update BiopharmaWatch en 2026-10-19T12:00:00.000Z Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/URGN/urogen-fda-acceptance-ugn-103-application BiopharmaWatch en 2026-10-19T12:00:00.000Z UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 https://www.biopharmawatch.com/news/SGP/spyglass-pharma-positive-4-year-data-bim-iol-system BiopharmaWatch en 2026-10-19T12:00:00.000Z SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System https://www.biopharmawatch.com/news/BDMD/baird-medical-regulatory-milestones-vietnam-egypt BiopharmaWatch en 2026-10-19T12:00:00.000Z Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology https://www.biopharmawatch.com/news/CLNN/clene-nda-submission-cnm-au8-als BiopharmaWatch en 2026-10-19T12:00:00.000Z Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2026-results-revenue-guidance-adjustment BiopharmaWatch en 2026-10-19T12:00:00.000Z Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-alkivia-results-acr-convergence-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 https://www.biopharmawatch.com/news/DMAC/diamedica-kol-webinar-update-fetal-growth-restriction BiopharmaWatch en 2026-10-19T12:00:00.000Z DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar https://www.biopharmawatch.com/news/DGX/current-screening-thresholds-miss-patients-primary-aldosterone BiopharmaWatch en 2026-10-19T11:57:00.000Z Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261019 BiopharmaWatch en 2026-10-19T11:53:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-eanm-2026 BiopharmaWatch en 2026-10-19T11:30:00.000Z Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 https://www.biopharmawatch.com/news/FTH/faeth-present-preclinical-data-piktor-esmo-2026 BiopharmaWatch en 2026-10-19T11:30:00.000Z Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 https://www.biopharmawatch.com/news/OGN/organon-third-quarter-2026-results-form-10-q BiopharmaWatch en 2026-10-19T11:30:00.000Z Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing https://www.biopharmawatch.com/news/BWAY/brainsway-collaboration-inland-psychiatry BiopharmaWatch en 2026-10-19T11:30:00.000Z BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q3-2026-results-resignation BiopharmaWatch en 2026-10-19T11:30:00.000Z Glass House Brands Reports Preliminary Unaudited Third Quarter Financial Results and Resignation of John Nichols Jr. from Board of Directors https://www.biopharmawatch.com/news/CYTK/cytokinetics-health-canada-approval-myorzo BiopharmaWatch en 2026-10-19T11:30:00.000Z Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/BIIB/biogen-present-new-data-nephrology-portfolio-asn-kidney-week BiopharmaWatch en 2026-10-19T11:30:00.000Z Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week https://www.biopharmawatch.com/news/CRMD/cormedix-fda-acceptance-rezzayo-prophylaxis-fungal-diseases BiopharmaWatch en 2026-10-19T11:30:00.000Z Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-strategic-prioritization BiopharmaWatch en 2026-10-19T11:15:00.000Z EyePoint Announces Strategic Prioritization https://www.biopharmawatch.com/news/XNCR/xencor-webcast-phase-1-xmab819-results BiopharmaWatch en 2026-10-19T11:01:00.000Z Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma https://www.biopharmawatch.com/news/AZN/astrazeneca-esmo-2026-pivotal-phase-iii-trials BiopharmaWatch en 2026-10-19T11:00:00.000Z AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib https://www.biopharmawatch.com/news/MANE/veradermics-vdphl01-phase-3-hair-loss-trial BiopharmaWatch en 2026-10-19T11:00:00.000Z Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-phase-ii-study-ivonescimab-ccrcc BiopharmaWatch en 2026-10-19T11:00:00.000Z Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fda-clearance-summit-trial BiopharmaWatch en 2026-10-19T11:00:00.000Z United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD https://www.biopharmawatch.com/news/CGEM/zipalertinib-nsclc-egfr-cns-metastases BiopharmaWatch en 2026-10-19T11:00:00.000Z Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases https://www.biopharmawatch.com/news/INSM/insmed-launches-brinsupr-tablets-japan BiopharmaWatch en 2026-10-19T11:00:00.000Z Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan https://www.biopharmawatch.com/news/IOVA/iovance-til-cell-therapy-esmo-congress-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-presentation-iasp-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/ATYR/atyr-pharma-research-collaboration-montefiore-einstein BiopharmaWatch en 2026-10-19T11:00:00.000Z aTyr Pharma Announces Research Collaboration with Montefiore Einstein https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-esmo-congress-2026-zolucatetide BiopharmaWatch en 2026-10-19T11:00:00.000Z Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 https://www.biopharmawatch.com/news/KMDA/kamada-participation-stifel-jefferies-conferences-november-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 https://www.biopharmawatch.com/news/IRON/disc-medicine-apollo-trial-results-bitopertin-epp BiopharmaWatch en 2026-10-19T11:00:00.000Z Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-educational-event-pkp2-acm BiopharmaWatch en 2026-10-19T11:00:00.000Z Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-fda-grant-mt-601-pancreatic-cancer BiopharmaWatch en 2026-10-19T11:00:00.000Z Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer https://www.biopharmawatch.com/news/EYPT/eyepoint-lucia-phase-3-results-duravyu-wet-amd BiopharmaWatch en 2026-10-19T11:00:00.000Z EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD https://www.biopharmawatch.com/news/HLN/haleon-health-house-interactive-wellness-popup-toronto BiopharmaWatch en 2026-10-19T11:00:00.000Z Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-esmo-2026-cancer-modalities BiopharmaWatch en 2026-10-19T10:59:00.000Z Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-launch-duloxetine-capsules BiopharmaWatch en 2026-10-19T10:55:00.000Z ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules https://www.biopharmawatch.com/news/BNTX/biontech-esmo-2026-oncology-pipeline-progress BiopharmaWatch en 2026-10-19T10:45:00.000Z BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 https://www.biopharmawatch.com/news/CAI/caris-life-sciences-launches-ai-cancer-detection-commercial BiopharmaWatch en 2026-10-19T10:30:00.000Z Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection https://www.biopharmawatch.com/news/IMUX/immunic-appoints-jaa-roberson-chief-people-officer BiopharmaWatch en 2026-10-19T10:30:00.000Z Immunic Appoints Jaa Roberson as Chief People Officer https://www.biopharmawatch.com/news/SNY/sanofi-insulin-manufacturing-facility-germany BiopharmaWatch en 2026-10-19T10:30:00.000Z Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany https://www.biopharmawatch.com/news/ONC/beone-medicines-esmo-2026-solid-tumor-franchise BiopharmaWatch en 2026-10-19T10:00:00.000Z BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 https://www.biopharmawatch.com/news/IDYA/darovasertib-potential-foundational-therapy-uveal-melanoma BiopharmaWatch en 2026-10-19T10:00:00.000Z IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-suzanne-monahan-svp-commercial BiopharmaWatch en 2026-10-19T10:00:00.000Z Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma https://www.biopharmawatch.com/news/BDSX/biodesix-digital-diagnostics-lung-pipeline BiopharmaWatch en 2026-10-19T10:00:00.000Z Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers https://www.biopharmawatch.com/news/BLTE/belite-bio-uplisting-nasdaq-global-select-market BiopharmaWatch en 2026-10-19T10:00:00.000Z Belite Bio Announces Uplisting to the Nasdaq Global Select Market https://www.biopharmawatch.com/news/TAK/entivyo-ulcerative-colitis-trial-results BiopharmaWatch en 2026-10-19T09:30:00.000Z First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication https://www.biopharmawatch.com/news/NUTX/nutex-health-2026-q3-financial-results-call BiopharmaWatch en 2026-10-19T09:30:00.000Z Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/LLY/lilly-omvoh-phase-3-results-pediatric-ulcerative-colitis BiopharmaWatch en 2026-10-19T08:40:00.000Z Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis https://www.biopharmawatch.com/news/ABBV/abbvie-abbv-466-crohns-disease-results BiopharmaWatch en 2026-10-19T08:00:00.000Z AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-19 BiopharmaWatch en 2026-10-19T07:15:25.407Z BIOA APJ program: Biotech Catalysts Oct 19, 2026 https://www.biopharmawatch.com/news/WAT/ultima-genomics-immune-profiling-study-uk-biobank BiopharmaWatch en 2026-10-19T07:05:00.000Z Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation https://www.biopharmawatch.com/news/EVAX/evaxion-three-year-follow-up-phase-2-trial-evx-01 BiopharmaWatch en 2026-10-19T07:00:00.000Z Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/OCS/oculis-predict-1-trial-licaminlimab-dry-eye BiopharmaWatch en 2026-10-19T06:00:00.000Z Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease https://www.biopharmawatch.com/news/TLX/telix-ekalia-collaborate-astatine-211-production-us BiopharmaWatch en 2026-10-19T05:30:00.000Z Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. https://www.biopharmawatch.com/news/NTRA/natera-esmo-2026-abstracts-ultrasensitive-mrd-technology BiopharmaWatch en 2026-10-18T22:10:00.000Z ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2026-oncology-data-presentation BiopharmaWatch en 2026-10-18T22:10:00.000Z AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio https://www.biopharmawatch.com/news/LLY/lilly-showcase-oncology-pipeline-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress https://www.biopharmawatch.com/news/INCY/incyte-oncology-data-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-azenosertib-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-abstracts-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MANE/veradermics-conference-call-phase-3-results-hair-loss BiopharmaWatch en 2026-10-18T22:00:00.000Z Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss https://www.biopharmawatch.com/news/IRON/disc-medicine-webcast-apollo-phase-3-results BiopharmaWatch en 2026-10-18T21:00:00.000Z Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)